Structural and functional properties of the Kunitz-type and C-terminal domains of Amblyomin-X supporting its antitumor activity

被引:1
作者
Morais, K. L. P. [1 ,2 ,3 ]
Ciccone, L. [4 ,5 ]
Stura, E. [4 ]
Alvarez-Flores, M. P. [1 ]
Mourier, G. [4 ]
Driessche, M. Vanden [4 ]
Sciani, J. M. [1 ]
Iqbal, A. [1 ,2 ]
Kalil, S. P. [1 ]
Pereira, G. J. [6 ]
Marques-Porto, R. [2 ]
Cunegundes, P. [1 ,3 ]
Juliano, L. [7 ]
Servent, D. [4 ]
Chudzinski-Tavassi, A. M. [1 ,2 ]
机构
[1] Butantan Inst, Ctr Excellence New Target Discovery CENTD, Sao Paulo, Brazil
[2] Butantan Inst, Lab Dev & Innovat, Sao Paulo, Brazil
[3] Univ Fed Sao Paulo, Dept Biochem, Sao Paulo, Brazil
[4] Univ Paris Saclay, Dept Medicaments & Technol St DMTS, CEA SIMoS, Gif Sur Yvette, France
[5] Univ Pisa, Dept Pharm, Pisa, Italy
[6] Univ Fed Sao Paulo, Dept Pharmacol, Sao Paulo, Brazil
[7] Univ Fed Sao Paulo, Dept Biophys, Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
antitumor drug candidate; Amblyomin-X; TFPI-like; endocytosis; protein crystallization; high content imaging (HCI); proteasome inhibitor; FACTOR PATHWAY INHIBITOR; DYNEIN LIGHT-CHAIN; TISSUE FACTOR; MITOCHONDRIAL DYSFUNCTION; CYTOPLASMIC DYNEIN; INTERMEDIATE CHAIN; ER STRESS; PEPTIDE; ACTIVATION; EXPRESSION;
D O I
10.3389/fmolb.2023.1072751
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Amblyomin-X is a Kunitz-type FXa inhibitor identified through the transcriptome analysis of the salivary gland from Amblyomma sculptum tick. This protein consists of two domains of equivalent size, triggers apoptosis in different tumor cell lines, and promotes regression of tumor growth, and reduction of metastasis. To study the structural properties and functional roles of the N-terminal (N-ter) and C-terminal (C-ter) domains of Amblyomin-X, we synthesized them by solid-phase peptide synthesis, solved the X-Ray crystallographic structure of the N-ter domain, confirming its Kunitz-type signature, and studied their biological properties. We show here that the C-ter domain is responsible for the uptake of Amblyomin-X by tumor cells and highlight the ability of this domain to deliver intracellular cargo by the strong enhancement of the intracellular detection of molecules with low cellular-uptake efficiency (p15) after their coupling with the C-ter domain. In contrast, the N-ter Kunitz domain of Amblyomin-X is not capable of crossing through the cell membrane but is associated with tumor cell cytotoxicity when it is microinjected into the cells or fused to TAT cell-penetrating peptide. Additionally, we identify the minimum length C-terminal domain named F2C able to enter in the SK-MEL-28 cells and induces dynein chains gene expression modulation, a molecular motor that plays a role in the uptake and intracellular trafficking of Amblyomin-X.
引用
收藏
页数:16
相关论文
共 67 条
  • [1] Pro-apoptotic effects of Amblyomin-X in murine renal cell carcinoma "in vitro"
    Akagi, Erica Mie
    de Sa Junior, Paulo Luiz
    Simons, Simone Michaela
    Bellini, Maria Helena
    Barreto, Sandra Alves
    Chudzinski-Tavassi, Ana Marisa
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2012, 66 (01) : 64 - 69
  • [2] The role of tissue factor pathway inhibitor in tumor growth and metastasis
    Amirkhosravi, Ali
    Meyer, Todd
    Amaya, Mildred
    Davila, Monica
    Mousa, Shaker A.
    Robson, Theresa
    Francis, John L.
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2007, 33 (07) : 643 - 652
  • [3] A new Factor Xa inhibitor from Amblyomma cajennense with a unique domain composition
    Batista, I. F. C.
    Ramos, O. H. P.
    Ventura, J. S.
    Junqueira-de-Azevedo, I. L. M.
    Ho, P. L.
    Chudzinski-Tavassi, A. M.
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2010, 493 (02) : 151 - 156
  • [4] Mechanisms of Cellular Uptake, Intracellular Transportation, and Degradation of CIGB-300, a Tat-Conjugated Peptide, in Tumor Cell Lines
    Benavent Acero, Fernando R.
    Perera Negrin, Yasser
    Alonso, Daniel F.
    Perea, Silvio E.
    Gomez, Daniel E.
    Farina, Hernan G.
    [J]. MOLECULAR PHARMACEUTICS, 2014, 11 (06) : 1798 - 1807
  • [5] QUANTITATIVE-ANALYSIS OF PROTEIN FAR UV CIRCULAR-DICHROISM SPECTRA BY NEURAL NETWORKS
    BOHM, G
    MUHR, R
    JAENICKE, R
    [J]. PROTEIN ENGINEERING, 1992, 5 (03): : 191 - 195
  • [6] Biodistribution and Pharmacokinetics of Amblyomin-X, a Novel Antitumour Protein Drug in Healthy Mice
    Boufleur, Pamela
    Sciani, Juliana Mozer
    Goldfeder, Mauricio
    Faria, Fernanda
    Branco, Vania
    Chudzinski-Tavassi, Ana Marisa
    [J]. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2019, 44 (01) : 111 - 120
  • [7] Amblyomin-X having a Kunitz-type homologous domain, is a noncompetitive inhibitor of FXa and induces anticoagulation in vitro and in vivo
    Branco, Vania G.
    Iqbal, Asif
    Alvarez-Flores, Miryam P.
    Sciani, Juliana M.
    de Andrade, Sonia A.
    Iwai, Leo K.
    Serrano, Solange M. T.
    Chudzinski-Tavassi, Ana M.
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2016, 1864 (10): : 1428 - 1435
  • [8] The second Kunitz domain of human tissue factor pathway inhibitor: Cloning, structure determination and interaction with Factor Xa
    Burgering, MJM
    Orbons, LPM
    vanderDoelen, A
    Mulders, J
    Theunissen, HJM
    Grootenhuis, PDJ
    Bode, W
    Huber, R
    Stubbs, MT
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1997, 269 (03) : 395 - 407
  • [9] Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa
    Camerer, E
    Huang, W
    Coughlin, SR
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (10) : 5255 - 5260
  • [10] Tuning the Anti-Angiogenic Effect of the P15 Peptide Using Cyclic Trypsin Inhibitor Scaffolds
    Chan, Lai Yue
    Du, Junqiao
    Craik, David J.
    [J]. ACS CHEMICAL BIOLOGY, 2021, 16 (05) : 829 - 837